Amorphous Ebselen Solid Dispersion for Higher Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ebselen formulations exhibit suboptimal bioavailability, resulting in insufficient maximum blood plasma concentration (Cmax) and area under the curve (AUC) for therapeutic efficacy, particularly in treating conditions like Meniere's Disease and ototoxicity.
Innovation Solution
Development of an amorphous solid dispersion (ASD) comprising an amorphous form of ebselen combined with a carrier polymer, using methods like spray drying or hot melt extrusion to enhance solubility and bioavailability, achieving a 2-fold increase in Cmax and AUC compared to control formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crystalline ebselen is used in conventional formulations, then the formulation is stable and easy to manufacture, but the bioavailability and maximum blood plasma concentration (Cmax) are insufficient for therapeutic efficacy
Solution Approach 1:
The patent transforms ebselen from its conventional crystalline state to an amorphous state, fundamentally changing its physical parameter (molecular arrangement). This parameter change increases solubility and bioavailability by eliminating the ordered crystal lattice structure that limits drug dissolution and absorption, while achieving therapeutic Cmax levels without requiring complex delivery systems
Solution Approach 2:
The patent creates an amorphous solid dispersion by combining amorphous ebselen with a carrier polymer matrix. This composite material approach embeds the amorphous drug within the polymer structure, maintaining the enhanced bioavailability of the amorphous form while providing the stability and manufacturability of a solid formulation, thus resolving the contradiction between improved bioavailability and formulation complexity
2Quantity of substance
If amorphous solid dispersion is used to enhance bioavailability, then Cmax and AUC are significantly improved, but the formulation complexity increases
Solution Approach 1:
The patent achieves a 2-fold increase in Cmax and AUC by changing the physical state of ebselen to amorphous form within the solid dispersion. This parameter change in molecular arrangement dramatically improves dissolution rate and extent, enabling sufficient blood plasma concentrations for therapeutic efficacy in conditions like Meniere's Disease and ototoxicity
Solution Approach 2:
The carrier polymer acts as an intermediary that stabilizes the amorphous ebselen within the solid dispersion matrix. The polymer prevents recrystallization of the drug while facilitating controlled release and dissolution, thereby maintaining the high bioavailability benefits of the amorphous form without requiring overly complex formulation strategies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous solid dispersion significantly enhances the maximum blood plasma concentration (Cmax) and area under the curve (AUC) of ebselen, improving therapeutic efficacy in conditions such as Meniere's Disease and ototoxicity.
Implementation Method 1
an amorphous solid dispersion (ASD) comprising an amorphous form of ebselen
Data Source
AI summary
The present disclosure provides an amorphous solid dispersion (ASD) comprising an amorphous form of ebselen. Also provided are pharmaceutical compositions and pharmaceutical dosage forms including the subject amorphous solid dispersion. Also provided are methods of delivering the subject ebselen pharmaceutical dosage forms to a subject to achieve an enhanced maximum blood plasma concentration (Cmax) for ebselen with respect to a control ebselen formulation, and an area under the curve (AUC) for both ebselen and an ebselen metabolite that is greater than that achieved with a control ebselen formulation.